Cover Image
Market Research Report
Product code 
968687

Plasma Therapy Market, By Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin, and Leukocyte-rich Fibrin ), By Application, By End-User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published: | Coherent Market Insights | 155 Pages | Delivery time: 2-3 business days

Price

Back to Top
Plasma Therapy Market, By Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin, and Leukocyte-rich Fibrin ), By Application, By End-User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Published: September 7, 2020
Coherent Market Insights
Content info: 155 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Title:
Plasma Therapy Market, By Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), and Leukocyte-rich Fibrin (L-PRF)), By Application (Infections Diseases, Dental, Nerve Injury, Cardiac Muscle Injury, and Other Applications), By End-User (Hospitals & Clinics, Research Institutes, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

  • Plasma therapy is a promising treatment against coronavirus, and many rare and serious disorders. The blood which is donated by the donor is processed in a processing facility to obtain plasma. Similarly, for treatment of coronavirus infected patients, the plasma is isolated from the donor. The donor is also the patient who is recovered from the infection. The donor plasma consists of antibodies which were generated in order to fight the antigens i.e. the coronavirus. The blood from the donor is processed in processing centers which is then injected in the blood of the patients.

Market Dynamics

  • Regulatory authorities are interested in conducting clinical trials for development of new treatment options for coronavirus infected patients. For instance, on 18th April 2020, The Drug Controller General of India accepted the proposal of the Indian Council of Medical Research (ICMR) for conducting clinical trials of convalescent plasma in COVID-19 patients. The ICMR has submitted a list of institutes which are interested in the trial.
  • In convalescent plasma therapy, the antibodies are recovered from the blood of patients who have recovered from COVID-19 and are injected in the blood of injected patients. The clinical trial aims to assess the efficacy of convalescent plasma to limit complications in COVID-19 patients and to evaluate the safety of treatment with anti SARS-CoV-2 plasma in coronavirus-infected patients. The rising number of clinical trials is expected to increase treatment options for coronavirus infected patients and spur the global plasma therapy market growth during the forecast period.
  • Companies are receiving approvals from regulatory authorities for the setup of a new manufacturing facility. For instance, in 2019, Takeda Pharmaceutical Company Limited received approval from the U.S Food and Drug Administration (U.S FDA) for its new pharmaceutical manufacturing facility near Covington, Georgia. The facility will produce FLEXBUMIN 25% [Albumin (Human), USP, 25% Solution]. The medicine is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome, and nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of newborns. The new facility will expand the product portfolio of the company which is expected to favor the global plasma therapy market growth during the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global plasma therapy market, market size (US$ 226.13 Mn), and compound annual growth rate (CAGR (14.1 %)) for the forecast period (2020-2027), considering 2019 as the base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global plasma therapy market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies.
  • Key players covered as a part of this study are Octapharma AG, China Biologic Products Holdings, Inc. Bio Products Laboratory Ltd., Kedrion S.p.A, Grifols, S.A., CSL, Biotest AG., Takeda Pharmaceutical Company Limited., DePuy Synthes, Regen Lab SA, LFB SA, and Immunotek Bio Centers.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global plasma therapy market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for plasma therapy market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Plasma Therapy Market, By Type:
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
  • Global Plasma Therapy Market, By Application:
  • Infectious Diseases
  • Dental
  • Nerve Injury
  • Cardiac Muscle Injury
  • Other Applications
  • Global Plasma Therapy Market, By End User:
  • Hospitals & Clinics
  • Research Institutes
  • Others
  • Global Plasma Therapy Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Type:
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
    • By Application
  • Infectious Diseases
  • Dental
  • Nerve Injury
  • Cardiac Muscle Injury
  • Other Applications
    • By End-User
  • Hospitals & Clinics
  • Research Institutes
  • Others
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Type:
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
    • By Application
  • Infectious Diseases
  • Dental
  • Nerve Injury
  • Cardiac Muscle Injury
  • Other Applications
    • By End-User
  • Hospitals & Clinics
  • Research Institutes
  • Others
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Type:
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
    • By Application
  • Treatments of Infections
  • Dental
  • Nerve Injury
  • Cardiac Muscle Injury
  • Other Applications
    • By End-User
  • Hospitals & Clinics
  • Research Institutes
  • Others
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Type:
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
    • By Application
  • Infectious Diseases
  • Dental
  • Nerve Injury
  • Cardiac Muscle Injury
  • Other Applications
    • By End-User
  • Hospitals & Clinics
  • Research Institutes
  • Others
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Type:
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
    • By Application
  • Infectious Diseases
  • Dental
  • Nerve Injury
  • Cardiac Muscle Injury
  • Other Applications
    • By End-User
  • Hospitals & Clinics
  • Research Institutes
  • Others
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Type:
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
    • By Application
  • Infectious Diseases
  • Dental
  • Nerve Injury
  • Cardiac Muscle Injury
  • Other Applications
    • By End-User
  • Hospitals & Clinics
  • Research Institutes
  • Others
  • Company Profiles
    • Octapharma AG
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
    • China Biologic Products Holdings, Inc.
    • Bio Products Laboratory Ltd.
    • Kedrion S.p.A.
    • Grifols, S.A.
    • CSL, Biotest AG.
    • Takeda Pharmaceutical Company Limited.
    • DePuy Synthes
    • Regen Lab SA
    • LFB SA
    • Immunotek Bio Centers.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Application
    • Market Snippet, By End-User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Strategies
  • Regulatory Scenario
  • New Product Launches/Approvals
  • Porter's Analysis
  • PEST Analysis

4. COVID - 19 Impact Analysis

  • Pre COVID-19 Market Scenario
  • Post COVID-19 Market Scenario
  • Strategies

5. Global Plasma Therapy Market, By Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Pure PRP
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Leucocyte-rich PRP
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Pure Platelet-rich Fibrin (PRF)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Leukocyte-rich Fibrin (L-PRF)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Plasma Therapy Market, By Application, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Dental
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Nerve Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Cardiac Muscle Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Other Applications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Plasma Therapy Market, By End User, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals & Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Plasma Therapy Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By End-User, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By End-User, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By End-User, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By End-User, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By End-User, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By End-User, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

9. Competitive Landscape

  • Company Profiles
    • Octapharma AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • China Biologic Products Holdings, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bio Products Laboratory Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Kedrion S.p.A
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Grifols, S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • CSL
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biotest AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Takeda Pharmaceutical Company Limited.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • DePuy Synthes
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Regen Lab SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • LFB SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Immunotek Bio Centers.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact